A Phase 4 interventional study of Belimumab plus Early Vaccination and Belimumab plus Late Vaccination in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-16.
Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 22nd largest by enrollment, is one of 5 that started in 2012, is one of 10 in phase 4, and was the 13th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc., a GSK Company is the lead sponsor of 13 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 21st largest by enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2012, is one of 5 in phase 4, and was the 16th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).
All patients in this study will receive belimumab plus standard therapy for SLE and vaccination against pneumococcus. Patients will be randomized to receive pneumococcal vaccination either 4 weeks prior (early vaccination group) or 24 weeks after (late vaccination group) their first belimumab dose. Vaccine response will be assessed 4 weeks after vaccine administration.
Key Inclusion Criteria:
Key Exclusion Criteria:
: Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HB surface antigen (HBsAg) and anti-HB core antibody (anti-HBc):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belimumab plus Early Vaccination
Biological: Belimumab plus Early Vaccination
Belimumab plus Late Vaccination
Biological: Belimumab plus Late Vaccination
Drug page: Belimumab
Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
Also known as: BENLYSTA™
Drug page: Belimumab
Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
Also known as: BENLYSTA™
Number of Participants With Positive Antibody Responses to at Least One of the 23 Pneumococcal Vaccine Serotypes 4 Weeks Post-vaccination
A positive immune response to at least one pneumococcal serotype is defined as a 2-fold or greater increase from pre-vaccination levels. For unquantifiable pre-vaccination antibody levels, a positive antibody response was considered as a post-vaccination level \>=0.6 micrograms (µg)/milliliter (mL). Post-vaccination pneumococcal titers were assessed on Day 28 (Week 4) prior to the first dose of belimumab in the early cohort and on Day 196 (Week 28) prior to the last belimumab dose in the late cohort. Evaluable participants for the early cohort included those who received the vaccination at Day 0 and had titers drawn at Week 4. For the late cohort, evaluable participants received at least 5 of the 7 doses of belimumab up through Week 24, received the vaccination at Week 24, and had titers drawn at Week 28.
Time frame: Four weeks after vaccination
Eligible participants with systemic lupus erythematosus (SLE) were randomized in 7:9 ratio to receive pneumonococcal vaccination either 4 weeks prior (early cohort) or 24 weeks after (late cohort) their first belimumab dose of 10 milligram (mg)/kilogram (kg) intravenously (IV).
| Milestone | Belimumab Plus Early Vaccination | Belimumab Plus Late Vaccination |
|---|---|---|
| Started | 34 | 45 |
| Completed | 28 | 41 |
| Not completed | 6 | 4 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Other reason | 2 | 0 |
A positive immune response to at least one pneumococcal serotype is defined as a 2-fold or greater increase from pre-vaccination levels. For unquantifiable pre-vaccination antibody levels, a positive antibody response was considered as a post-vaccination level \>=0.6 micrograms (µg)/milliliter (mL). Post-vaccination pneumococcal titers were assessed on Day 28 (Week 4) prior to the first dose of belimumab in the early cohort and on Day 196 (Week 28) prior to the last belimumab dose in the late cohort. Evaluable participants for the early cohort included those who received the vaccination at Day 0 and had titers drawn at Week 4. For the late cohort, evaluable participants received at least 5 of the 7 doses of belimumab up through Week 24, received the vaccination at Week 24, and had titers drawn at Week 28.
| Participants | Belimumab Plus Early Vaccination | Belimumab Plus Late Vaccination |
|---|---|---|
| Number of Participants With Positive Antibody Responses to at Least One of the 23 Pneumococcal Vaccine Serotypes 4 Weeks Post-vaccination | 32 | 40 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to 8 weeks following administration of the last dose of belimumab).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab Plus Early Vaccination | — | 4/34 (11.8%) | 21/34 (61.8%) |
| Belimumab Plus Late Vaccination | — | 3/45 (6.7%) | 32/45 (71.1%) |
| Event | Belimumab Plus Early Vaccination | Belimumab Plus Late Vaccination |
|---|---|---|
| Any eventCardiac disorders | 2/34 | 1/45 |
| Any eventRenal and urinary disorders | 2/34 | 0/45 |
| Any eventPsychiatric disorders | 0/34 | 2/45 |
| Cardiac failure congestiveCardiac disorders | 1/34 | 0/45 |
| Pericarditis lupusCardiac disorders | 1/34 | 0/45 |
| Chronic kidney diseaseRenal and urinary disorders | 1/34 | 0/45 |
| Glomerulonephritis proliferativeRenal and urinary disorders | 1/34 | 0/45 |
| Any eventInvestigations | 1/34 | 0/45 |
| Transaminases increasedInvestigations | 1/34 | 0/45 |
| Any eventMetabolism and nutrition disorders | 1/34 | 0/45 |
| Event | Belimumab Plus Early Vaccination | Belimumab Plus Late Vaccination |
|---|---|---|
| Any eventInfections and infestations | 10/34 | 20/45 |
| Any eventGastrointestinal disorders | 7/34 | 12/45 |
| Any eventMusculoskeletal and connective tissue disorders | 6/34 | 11/45 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/34 | 10/45 |
| NauseaGastrointestinal disorders | 6/34 | 9/45 |
| Any eventNervous system disorders | 5/34 | 5/45 |
| Gastroenteritis viralInfections and infestations | 1/34 | 6/45 |
| DizzinessNervous system disorders | 4/34 | 2/45 |
| Any eventRespiratory, thoracic and mediastinal disorders | 4/34 | 3/45 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/34 | 3/45 |
| Age, Continuous(Years) | Belimumab Plus Early Vaccination | Belimumab Plus Late Vaccination | Total |
|---|---|---|---|
| Mean | 41.0 ± 12.57 | 38.6 ± 12.31 | 39.6 ± 12.40 |
| Sex: Female, Male(Participants) | Belimumab Plus Early Vaccination | Belimumab Plus Late Vaccination | Total |
|---|---|---|---|
| Female | 29 | 43 | 72 |
| Male | 5 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | Belimumab Plus Early Vaccination | Belimumab Plus Late Vaccination | Total |
|---|---|---|---|
| White | 25 | 27 | 52 |
| Black or African American | 8 | 12 | 20 |
| Asian | 1 | 4 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Mixed Race | 0 | 1 | 1 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from May 2012 to primary completion in Sep 2015, 39 months.
Results were first posted in Jul 2016, 10 months after primary completion.
Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's 39 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →
Human Genome Sciences Inc., a GSK Company →